A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
Running, not enrolling · Phase 1/Phase 2
Conditions studied: Extensive Stage Small Cell Lung Cancer
In brief
This study aims to establish a safe and well tolerated dose of \[177Lu\]Lu-DOTA-TATE in combination with carboplatin, etoposide and atezolizumab in this setting and to assess preliminary efficacy of this combination treatment versus the combination of carboplatin, etoposide, and atezolizumab.The study will be essential to assess a new potential therapeutic option in participants with this aggressive cancer type.
Key facts
- Study ID
- NCT05142696
- Run by
- Novartis Pharmaceuticals
- People needed
- 55
- Starts
- 2022-07-13
- Expected to finish
- 2028-03-07
- Last updated by the study team
- 2026-08-03
Who can join
Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Georgetown University Lombardi Cancer Center — Washington D.C., District of Columbia, United States
- AdventHealth — Orlando, Florida, United States
- University Cancer and Blood Center LLC — Athens, Georgia, United States
- University of Kentucky — Lexington, Kentucky, United States
- St Louis University — St Louis, Missouri, United States
- Hackensack University Medical Ctr — Hackensack, New Jersey, United States
- University Hospitals Of Cleveland — Cleveland, Ohio, United States
- Fox Chase Cancer Center — Philadelphia, Pennsylvania, United States
- Novartis Investigative Site — Linz, Upper Austria, Austria
- Novartis Investigative Site — Vienna, Austria
- Novartis Investigative Site — Montreal, Quebec, Canada
- Novartis Investigative Site — Beijing, China
- Novartis Investigative Site — Shanghai, China
- Novartis Investigative Site — Olomouc, Czechia
- Novartis Investigative Site — Lille, France
- Novartis Investigative Site — Marseille, France
- Novartis Investigative Site — Montpellier, France
- Novartis Investigative Site — Essen, Germany
- Novartis Investigative Site — Beersheba, Israel
- Novartis Investigative Site — Ramat Gan, Israel
- Novartis Investigative Site — Tel Aviv, Israel
- Novartis Investigative Site — Singapore, Singapore
- Novartis Investigative Site — Singapore, Singapore
- Novartis Investigative Site — Seoul, South Korea
- Novartis Investigative Site — Seoul, South Korea
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.